News

Brookfield wants to build AI data centers in London’s answer to Wall Street

BKFDF, BKFAF, BKFOF, BKFPF, BROXF, AI, BRFAF, BRFCF, BRCFF

Brookfield's CEO said the firm is bringing data centers to London's Canary Wharf, as demand for AI infrastructure in the U.K. soars.

Amplitude (AMPL) Moves 11.8% Higher: Will This Strength Last?

AMPL, QXO

Amplitude (AMPL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SpaceX may emerge as ultimate blueprint for new wave of mega-cap IPOs

"It would not surprise me at all to see a similar dynamic play out with some of these [IPOs] set to come in the months ahead," the Kathmere Capital CIO says.

Buying the American Dream: The best tools, strategies and hacks for first-time house hunters

Here's everything you need to know about buying your first home, including mortgage calculators, interest rate estimators and best mortgage lenders.

Americans are paying record prices for steak. Here's why demand isn't cracking

Despite record beef prices, Americans aren't giving up steak. Consumers are treating beef as an affordable luxury and prioritizing it for special occasions.

Restrictive immigration policies are changing the composition of the healthcare workforce

CNBC’s Sharon Epperson reports on how restrictive immigration policies affect the healthcare workforce.

Palantir shares have struggled this year. D.A. Davidson says buy the dip

A, D

Analyst Gil Luria upgraded the AI and defense software stock to buy from neutral.

LAMR Crosses Above Average Analyst Target

LAMR

In recent trading, shares of Lamar Advertising Co (Symbol: LAMR) have crossed above the average analyst 12-month target price of $156.17, changing hands for $156.64/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade

Yelp Reaches Analyst Target Price

YELP

In recent trading, shares of Yelp Inc (Symbol: YELP) have crossed above the average analyst 12-month target price of $26.11, changing hands for $26.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation,

UroGen Pharma Reaches Analyst Target Price

URGN

In recent trading, shares of UroGen Pharma Ltd (Symbol: URGN) have crossed above the average analyst 12-month target price of $36.88, changing hands for $37.94/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on va